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Abstract
The G-protein coupled receptor (GPCR), Cysteine (C)-X-C Receptor 4 (CXCR4), plays an important role in prostate cancer
metastasis. CXCR4 is generally regarded as a plasma membrane receptor where it transmits signals that support
transformation, progression and eventual metastasis. Due to the central role of CXCR4 in tumorigenesis, therapeutics
approaches such as antagonist and monoclonal antibodies have focused on receptors that exist on the plasma membrane.
An emerging concept for G-protein coupled receptors is that they may localize to and associate with the nucleus where
they retain function and mediate nuclear signaling. Herein, we demonstrate that CXCR4 associated with the nucleus of
malignant prostate cancer tissues. Likewise, expression of CXCR4 was detected in nuclear fractions among several prostate
cancer cell lines, compared to normal prostate epithelial cells. Our studies identified a nuclear pool of CXCR4 and we
defined a nuclear transport pathway for CXCR4. We reveal a putative nuclear localization sequence (NLS), ‘RPRK’, within
CXCR4 that contributed to nuclear localization. Additionally, nuclear CXCR4 interacted with Transportinb1 and
Transportinb1-binding to CXCR4 promoted its nuclear translocation. Importantly, Gai immunoprecipitation and calcium
mobilization studies indicated that nuclear CXCR4 was functional and participated in G-protein signaling, revealing that the
nuclear pool of CXCR4 retained function. Given the suggestion that functional, nuclear CXCR4 may be a mechanism
underlying prostate cancer recurrence, increased metastatic ability and poorer prognosis after tumors have been treated
with therapy that targets plasma membrane CXCR4, these studies addresses a novel mechanism of nuclear signaling for
CXCR4, a novel mechanism of clinical targeting, and demonstrate an active nuclear pool that provides important new
information to illuminate what has been primarily clinical reports of nuclear CXCR4.
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Introduction
Prostate cancer (PCa) is the second leading cause of increased
cancer incidence and cancer-related deaths among men in the
United States [1,2]. Despite treatment, the high mortality rates in
PCa are attributed to metastasis, which is the main obstacle in PCa
treatment [3]. Several molecules and mechanisms contribute to
cancer cell metastasis. For instance, chemoattractant cytokines
(chemokines) enhances the metastatic potential of PCa by binding
and activating a family of G-protein coupled receptors (GPCRs)
[4,5,6,7] that initiate signals to enhance cell adhesion, invasion
and movement, and subsequently, tumor survival at the new site of
metastasis. GPCRs constitute the largest family of transmembrane
plasma membrane (PM) receptors [8]. In conventional GPCR
signaling, receptors are localized to the PM and influence the
activity of PM-localized enzymes, ion channels, and/or second
messengers. Their activation by an appropriate ligand triggers
signaling through G-protein alpha (Ga) and/or beta-gamma (Gbc)
subunits [9], leading to context-dependent outcomes, which may
positively and/or negatively regulate the activity of effector
molecules in signaling cascades within the cell [10,11]. Addition-
ally, activated GPCRs also trigger a series of molecular
interactions that allow for feedback regulation of G-protein
coupling and receptor endocytosis to attenuate receptor signals
[12,13,14,15,16,17,18]. Mu¨ller et al. initially described the
involvement of chemokine GPCR receptors in cancer metastasis
[19] and Akashi et al. reported that the chemokine GPCR,
CXCR4, was highly expressed in human malignant PCa
compared to normal prostate [20]. Numerous studies have
documented the involvement of CXCR4 in key steps of PCa
metastasis: (i) signaling; [21,22]; (ii) invasion and migration [23];
and (iii) the establishment of a vascular network [24]. Hence,
several therapeutics for cancer cell metastasis have been designed
to antagonize CXCR4-mediated signaling [25,26]. In convention-
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al CXCR4 signaling, stromal cell-derived factor 1 alpha (SDF1a)
is the exclusive ligand for CXCR4 [27], which leads to activation
of pathways makes this receptor favorable to tumorigenesis: (i) G-
protein coupled receptor (GPCR) signaling; (ii) PI3K/AKT;
(iii)MAPK; (iv) JAK/STAT; (v) Src kinase and (vi) HER2
[28,29,30].
Interestingly, GPCRs have been detected in subcellular
organelles distinct from its classical PM location [31]. These
organelles include the Golgi apparatus [32], endoplasmic reticu-
lum [33], the cytoskeleton [34] and the nucleus/nuclear mem-
brane [35]. Hanyaloglu and von Zastrow postulated that default
recycling of GPCRs by endosomes may contribute to enhanced re-
delivery of GPCRs to the PM, or to alternate organelles within the
cell, without destroying their signaling capacity [36]. Nevertheless,
these alternately-localized GPCR receptors reveal a new level of
complexity that may be important in modulating their function.
An increasing number of GPCRs have been observed within the
nucleus or nuclear membrane, such as lysophosphatidic acid
receptors, metabotropic glutamate receptors, platelet-activating
factor receptors, angiotensin 2 type I receptors, prostaglandin
receptors, endothelin receptors, gonadotropin releasing hormone
type I receptor [37] and b-adrenergic receptors
[38,39,40,41,42,43,44]. Nuclear GPCRs have been suggested to
regulate a number of physiological processes, including cell
proliferation, survival, inflammatory responses, tumorgenesis,
DNA synthesis and transcription [43,45,46,47,48,49,50]. Nuclear
GPCRs may be constitutively active, or activated by internal,
newly synthesized ligands that are bound for secretion [51].
Subsequently, classical second messenger signaling pathways, such
as adenylyl cyclase-induced Protein Kinase A (PKA) activation
[38], phospholipase-induced release of intranuclear calcium,
diacyglycerol-induced Protein Kinase C (PKC) [39,52], ERK1/
2, p38 MAP Kinases and Protein Kinase B (PKB) [49,50] have
been shown to be activated by nuclear GPCRs.
Nuclear localization of proteins is dictated by nuclear import
and export through nuclear pore complexes [53]. Small proteins
(,30–50 kDa) can pass through the nuclear pore by free diffusion;
however, most cargo proteins require active transport to enter the
nucleus [54]. Larger proteins use active transport mechanisms,
which require assistance by transport proteins [55,56,57]. Many
proteins targeted to the nucleus contain a classical nuclear
localization signal (NLS) that is recognized by a heterodimeric
import receptor comprised of importin alpha and importin beta.
Many of these receptors directly recognize cargo proteins and
target them directly to the nuclear pore [58]. In the case of this
large family, the targeting signals within the cargo proteins are
often not well-defined [59]. Each protein that localizes to the
nucleus must possess a functional NLS or is required to bind to
cargo proteins which possess a NLS(s). Importin alpha recognizes
the NLS in the cargo protein while importin beta targets the
import complex to the nuclear pore [58,60]. Importin beta is part
of a larger family of transport receptors often termed importins/
exportins [59].
While a putative NLS has been identified in CXCR4 [61], the
function of this nuclear targeting signal in the context of CXCR4
has not been examined. A distinct importin-dependent transport
pathway has been implicated in the transport of C-C chemokine
receptor type 2 (CCR2) [62]. Favre et al. found that an engineered,
HA-tagged CCR2 associated with a member of the importin
family of nuclear transport receptors, Transportinb1 (TRN1), in a
CCR2-null cell line [62]. An interaction of CCR2 with TRN1 was
required to detect CCR2 in nuclear fractions, suggesting that
CCR2 transported to the nucleus via TRN1 [62]. TRN1 has been
implicated in GPCR internalization and desensitization [63].
Furthermore, TRN1 serves as a receptor for NLS-null proteins in
NLS-containing cargo substrates [64], making it an essential
protein for import through the nuclear pore complex [65]. Taken
together, these studies suggest that both the classical nuclear
import machinery and TRN1 are candidates that play a role in
CXCR4 nuclear translocation [66].
Nuclear CXCR4 protein expression has been observed in
malignant hepatocellular, colorectal, renal cell and nasopharyn-
geal carcinomas [67,68,69,70]. These studies, however, were
reported as clinical observations, and failed to investigate the
mechanisms of CXCR4 localization or any biological function
associated with the nuclear receptor. These data are consistent
with reports that have demonstrated functional GPCRs associated
with the nucleus, and further contribute to ongoing cancer
therapeutic interventions against CXCR4. Importantly, a func-
tional nuclear CXCR4 may contribute to PCa relapse despite
current antagonists and monoclonal antibodies against PM-bound
CXCR4 and may not be designed to cross the PM, which would
be required to antagonize active CXCR4 at the nucleus.
Furthermore, identification of transport pathways required for
nuclear localization of CXCR4 may reveal additional targets for
therapeutic development to hinder prostate cancer metastasis and
improve patient survival.
Materials and Methods
Cell Culture, Antibodies and Reagent Conditions
PC3, DU145, 22RV1 human prostate cancer cell lines (PCa),
RWPE1 human prostate cell line and 293T human embryonic
kidney cell line were obtained from American Type Culture
Collection (ATCC). PC3, DU145, 22RV1 and 293T cells were
maintained in complete RPMI media: RPMI 1640 containing
10% fetal bovine serum (FBS), 1% non-essential amino acids and
1% antibiotic-antimycotic at 37uC in 5% CO2. RWPE1 cells were
maintained in keratinocyte serum-free medium (KSFM) contain-
ing 50 mg/ml gentamycin, 0.05 mg/ml bovine pituitary extract
(BPE), and 5 ng/ml epidermal growth factor (Invitrogen) at 37uC
in 5% CO2. All cells were maintained at 60% to 80% confluency.
PC3 cells were originally isolated from a prostate vertebral
metastasis, while DU145 cells were obtained from prostate brain
metastasis. 22RV1 cells were from a human prostate carcinoma
epithelial cell line derived from a xenograft that was serially
propagated in mice, and RWPE1 cells were isolated from normal
human prostate epithelium. Cell culture supplies and kanamycin
sulfate (61-176-RG) were from MediaTech; SDF1a (300-28A) was
from PeproTech. The following reagents and human antibodies
were from Cell Signaling: 106cell lysis buffer (9803), mouse anti-
rabbit IgG (5127), anti-CD44 (156-3C11), anti-GFP (2956S) and
anti-Gai (5290). Anti-CXCR4 (MAB172) was from R&D Systems.
Anti-Topoisomerase1 (SC-271285), anti-Lamin A/C (SC-20681),
Fusin (H-118)-CXCR4 (SC-9046), Fusin (4G10)-CXCR4 (SC-
53534), anti-Fibronectin IgG2B (SC-271098), anti-GFP (sc-9996),
Protein A/G Plus-Agarose beads (SC-2003), anti-Karyopherinb2
(SC-166127), Karyopherinb2 siRNA (h) (SC-35737) and DAPI
(SC-3598) were from Santa Cruz Biotech. NE-PER Nuclear and
Cytoplasmic Extraction Kit (78833), Protease Inhibitor Cocktail
Kit (78410) and Halt TM Phosphate Inhibitor Cocktail (78420)
were from Thermo Scientific. Anti-aTubulin (T5168), Anti-bActin
(A5441) Triton X-100 (T8532) and propidium iodide (P4170) were
from Sigma-Aldrich. Prostate disease spectrum tissue array
(PR8011) was purchased from Biomax. JetPRIMEH Polypus
transfection reagent (114-07) was from VWR International.
Nonidet P-40 Substitute (M158) was from BioExpress and
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FluoForte Calcium Assay Kit (ENZ-51016) was from Enzo Life
Sciences.
Characterization of CXCR4 IgG2B (R&D systems) Antibody
Specificity of anti-human CXCR4 mouse monoclonal antibody
(R&D Systems) to CXCR4 protein was determined by immuno-
precipitation and western blot analysis using CXCR4-positive PC3
and CXCR4-null 293T whole cell lysates. Briefly, PC3 and 293T
cells (56106) were grown on 100 mm dishes in complete media
overnight, followed by incubation in RPMI only (serum-starvation)
for 24 hrs. Cell were washed with 16 phosphate-buffered saline
(PBS) and harvested in 16 Cell Signaling lysis buffer. Equal
protein concentrations were estimated by Bradford assay (BioRad)
and equal amounts were assessed for western blot analysis with
CXCR4-IgG2B mouse monoclonal antibody or 1 mg of super-
natant was immunoprecipitated (IP) with CXCR4-IgG2B mouse
monoclonal antibody or Fibronectin-IgG2B mouse monoclonal
antibody overnight at 4uC (Santa Cruz; 1 mg per 250 mg of
protein), followed by incubation with Protein A/G Plus-Agarose
beads for 2 hrs at 4uC. Protein-bound agarose beads were
separated from lysates by a series of 3 washes with 16 PBS and
centrifugation (max speed/2 min/room temperature [RT]). Beads
in Lammelli buffer were separated by 10% SDS-PAGE, trans-
ferred to polyvinylidenefluoride (PVDF) membranes and probed
for CXCR4-IgG2B (1:1000). To confirm that PC3 cells expressed
Fibronectin, 25 mg of whole cell lysate was harvested for western
blot analysis. Beta-actin was used as a loading control.
Immunohistochemistry (IHC)
IHC analysis was performed on a prostate disease spectrum
tissue array (Biomax) ranging from normal to high grade
metastatic tissues. The array consisted of 80 total tissue cores
including adenocarcinoma, metastatic, hyperplasia, chronic in-
flammation, adjacent normal tissue and normal tissue. Each
individual core had a diameter of 1.5 mm and a thickness of
0.5 mm. Briefly, formalin-fixed, paraffin-embedded specimens
were retrieved in washes of xylene, ethanol, and antigen retrieval
solution, pH 6.0, (Biocare Medical) at 125uC for 30 sec. Speci-
mens were neutralized in 0.3% hydrogen peroxide for 15 min at
room temperature (RT), washed with 16 PBS in a humidified
chamber and blocked with blocking solution (5% normal goat
serum/Tris-buffered saline/Tween-20; TBST) for 30 min.
CXCR4 was detected with a mouse anti-human CXCR4
monoclonal antibody (R&D Systems; 1:1000) in blocking solution
overnight at 4uC, followed by a biotinylated affinity purified goat
anti-mouse IgG (H+L) secondary antibody (Vector Laborato-
ries;1:1000), in blocking solution for 30 min at RT. Specimens
were washed thoroughly between incubations, developed in
diaminobenzidine (Vector Laboratories) for 3 min at RT, and
counterstained with Meyer’s hematoxylin using standard tech-
niques. A negative control tissue sample was prepared by
incubating in biotinylated affinity purified goat anti-mouse IgG
(H+L) antibody, only, as described above. The specimens were
analyzed and photographed by Dr. Dezhi Wang [71] at the
Center for Metabolic Bone Disease Core Laboratory, UAB School
of Medicine, Birmingham, Alabama. The distribution of positive
cells for CXCR4 was recorded to portray the diffuse or focal
nature of the positive cells as sporadic (positive cells ,5%); focal
(positive cells .11% but less than 50%); or diffuse (positive cells
.50%) according to the average density of positive cells for
CXCR4 (DAB stained), to see the obvious difference in strength of
CXCR4 expression.
Histomophometry Measurement of Staining Intensity for
CXCR4 in Prostate Cancer Tissues
The average density of positive cells (DAB stained) was
measured by using BioquantH Image Analysis Software (RtmBo-
metrics) and an Olympus BX51 Microscope with a Q-Imaging
camera. The software analyzed an average group of pixels and
returned a data value based on the color value of the pixels in
stained samples. Three random fields of prostate tissues were
selected at a magnification of (400X) for each section based on the
size of the tissue. In each random area, those cells (a group of
pixels) that were stained positively (brown) with the CXCR4
antibody were selected by the thresholding tool of the software.
The specimen light source is known to affect density measurement;
therefore, all sections were measured utilizing the same back-
ground correction supplied by Bioquant.
Subcellular Fractionation
PCa and normal prostate epithelial cells (16106) were serum-
starved for 3 hrs (22RV1 and RWPE1) or 24 hrs (PC3 and
DU145), prior to treating with SDF1a (100 ng/ ml) for 30 min.
Subcellular fractionations were performed per the manufacturer’s
instructions (Thermo Scientific). Briefly, cells were lysed in a series
of buffers and centrifugation steps to obtain a non-nuclear fraction
and an intact nuclear pellet, followed by further lysing to isolate
nuclear proteins. Forty to one hundred micrograms of nuclear and
non-nuclear fractions were separated by SDS-PAGE electropho-
resis and transferred to PVDF membranes. Expression of CXCR4
or GFP-CXCR4 fusion protein was detected with a mouse
monoclonal GFP antibody (Santa Cruz; 1:500) or anti-human
CXCR4 antibody (R&D Systems; 1:1000). Anti-topoisomerase I
(Santa Cruz; 1:1000) and anti-CD44 (Cell Signaling; 1:1000)
antibodies were used to ensure the integrity of fractions and as
loading controls. X-ray films were scanned and Quantity One
software program was used for densitometry analysis.
Indirect Immunocytochemistry (ICC) for CXCR4
Cells (36105) were plated on glass coverslips (Fisher), serum-
starved as described, prior to treatments with SDF1a (100 ng/ ml).
Cells were fixed with ice-cold 100% methanol for 5 min at 220˚C
and washed with 16 PBS. Non-specific proteins were blocked in
blocking solution (3% normal donkey serum/1% BSA/0.1%
Triton X-100 in 16 PBS) for 30 min at RT, prior to incubating
with CXCR4 (R&D Systems, 1:100), Lamin A/C (Santa Cruz,
1:100), or GFP mouse monoclonal antibody (Santa Cruz, 1:100) in
blocking solution at 4˚C overnight. Secondary detection was with
Cy3-conjugated donkey anti-mouse IgG or FITC conjugated anti-
rabbit IgG (Jackson Immuno Research, 1:1000) in blocking
solution at RT for 1 hr, followed by three washes in 16 PBS. In
some cases, nuclei were detected with propidium iodide (1 mg/ ml)
or DAPI (1:250) in 16PBS prior to mounting in Aqua-Polymount
(Polyscience, Inc). Images were taken at Georgia Institute of
Technology, Atlanta, GA with a 63x Plan-Apochromat 63x/1.40
Oil DIC objective on a Zeiss LSM-510 UV Confocal Microscope
at excitation 488 nm for FITC and 543 nm for Cy3 or at Clark
Atlanta University, Atlanta, GA with Axiovision software 4.8.2 on
a Zeiss Axio Imager.z1 fluorescence microscope at 406 magni-
fication at excitation 470 nm for FITC, 358 nm for DAPI and
551 nm for Cy3.
Mutagenesis
R146A and R148A point mutations within the NLS, and
deletion of the NLS, within GFP-CXCR4 fusion protein were
generated using the Quik Change XL Site-Directed Mutagenesis
Nuclear CXCR4 in Metastatic Prostate Cancer Cells
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Kit (Stratagene); pEGFPN1-CXCR4 served as the template [72].
The forward and reverse primers of R146A, R148A and the
deleted NLS were (Integrated DNA Technologies): (i) R146A:
FWD59-CACGCCACCAACAGTCAGGCACCAAGGAAGCT-
GTTGGCTG-39, REV 59-CAGCCAACAGCTTCCTTGG-
TGCCTGACTGTTGGTGGCGTG-39; (ii) R148A: FWD5`-
CCAACAGTCAGAGGCCAGCGAAGCTGTTGGCTGAAA-
3`, REV 5`-TTTCAGCCAACAGCTTCGCTGGCCTCTGAC-
TGTTGG-3`; and (iii) NLS deletion: FWD59-CGCCACCAA-
CAGTCAGCTGTTGGCTGAAAAGG-39 and REV59-CCTT-
TTCAGCCAACAGCTGACTGTTGGTGGCG-39. The resul-
tant plasmids were pEGFPN1-CXCR4R146A, pEGFPN1-
CXCR4R148A and pEGFPN1-CXCR4DNLS. Positive
CXCR4 mutant clones were selected with kanamycin and
further purified by maxi-prep (Omega Bio-tek). Accuracy of the
mutations was confirmed by DNA sequencing on an ABI
3130 xl Gene Analyzer Sequencer at Morehouse School of
Medicine, Atlanta, GA.
Figure 1. Immunohistochemical (IHC) Staining of Prostate Tissues for CXCR4. A, A human prostate tissue array, ranging from normal to
high-grade prostate cancer, was evaluated by IHC for CXCR4 expression using standard methods. Samples were evaluated at magnification 40X,
using a Q-Imaging camera of Olympus BX51 Microscope with BioquantH Image Analysis Software (RtmBometrics). Normal prostate tissues
demonstrated slightly weak or undetectable brown staining for CXCR4 (positive cells,5%), and no CXCR4 expression in the nucleus. Representative
low grade prostate tissue (grade 2, stage II, T2N0M0, adenocarcinoma) demonstrated random/focal positive staining for CXCR4 in the nucleus (positive
cells .11%, but less than 50%), indicating low expression of CXCR4. Representative high grade metastatic prostate tissue (grade 4, stage IV, T4N1M1,
adenocarcinoma) demonstrated diffuse/intense staining (positive cells .50%), indicating high expression for CXCR4 in the nucleus. Scale bar
represents 50 mm. B, CXCR4 IgG2B mouse monoclonal antibody was evaluated for specificity to CXCR4 protein by western blot analysis in PC3
(CXCR4 positive) or 293T (CXCR4 null) cell lines. C, CXCR4 antibody was evaluated for specificity to CXCR4 protein by immunoprecipitation for CXCR4
and western blot analysis for CXCR4. D, CXCR4 IgG2B antibody was evaluated for specificity to CXCR4 protein by immunoprecipitation with
Fibronectin IgG2B mouse monoclonal antibody (unrelated isotype control) and western blot analysis for CXCR4; expression of Fibronectin protein
was confirmed by western blot analysis. Beta-actin was used as a loading control.
doi:10.1371/journal.pone.0057194.g001
Table 1. PSORT Prediction of Nuclear Localization Sequence
(NLS) in CXCR4.
Gene
Nuclear localization
sequence
Amino acid
sequence Position
CXCR4 RPRK Arg, Pro, Arg, Lys 146 to 149
PSORT is a NLS prediction server to determine the NLS scores of amino acid
residues of a protein. It receives amino acid sequence information of a source,
e.g., human CXCR4, as inputs and subsequently analyzes the input sequence by
applying stored rules for various sequence features of known protein sorting
signals. Finally, it reports possible sequences for the input protein to be
localized at each candidate site with additional information. The human CXCR4
sequence (NCBI assession number NP_001008540) was searched by the server,
which provided a NLS score for each of the 356 residues comprising CXCR4.
http://psort.hgc.jp/.
doi:10.1371/journal.pone.0057194.t001
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Transient Transfections
Transient transfections were performed with 2 mg of concen-
trated DNA and jetPRIMEH Polypus transfection, per the
manufacturers’ instructions. Briefly, PC3 cells were incubated
with jetPRIMEH-DNA complexes in 15% FBS/RPMI for 4 hrs
and the media was replaced with 15% FBS in RPMI for an
additional 18 hrs, prior to serum-starvation (24 hrs). Cells were
then harvested for respective experiments.
Expression of Transportinb1 (TRN1)
Serum-starved cells (56106) were treated with SDF1a for
30 min prior to harvesting 60 mg of whole cell lysates for western
blot analysis. Expression of TRN1 was detected with a mouse
monoclonal antibody (Santa Cruz; 1:1000); a-Tubulin or b-Actin
was used as a loading control.
Immunoprecipitation
One milligram of PC3 whole cell lysates were immunoprecip-
itated for CXCR4 (Santa Cruz; 1 mg per 250 mg of protein)
overnight at 4uC, followed by incubation with Protein A/G Plus-
Agarose beads (Santa Cruz) for 2 hrs at 4uC. CXCR4-bound
agarose beads were separated from lysate by a series of 3 washes
with PBS and centrifugation at maximum speed for 1 min at 4uC.
Beads were processed for western blot analysis for TRN1 (Santa
Cruz; 1:1000) and subsequently reprobed for CXCR4 with rabbit
anti-CXCR4 (Santa Cruz, 1:500) antibody followed by incubation
with mouse anti-rabbit IgG (Cell Signaling) secondary antibody.
Thirty micrograms of the supernatant obtained after incubation
with agarose beads were also separated by 10% SDS-PAGE, and
processed for western blot analysis for CXCR4 as described in
characterization of CXCR4 antibody.
Short Interfering RNA Transfection
Transient transfection of TRN1 specific siRNA (Santa Cruz)
was performed on PC3 cells plated on glass coverslips using
JetPRIMEH. Briefly, cells (26105) were plated in 35 mm, 6 well
dishes and transfected with 50 nM TRN1-siRNA (Santa Cruz) in
15% FBS/RPMI media at 37uC in 5% CO2 for 24 hours.
Subsequently, transfected cells were serum-starved for 24 hrs,
prior to immunocytochemistry analysis.
Immunoprecipitation of Gai
Serum-starved cells (56106) were treated with SDF1a for
30 min prior to harvesting for immunoprecipitation. Briefly, cells
were washed in 16PBS and gently scraped in NP-40 lysis buffer
(16PBS pH 7.4, 0.1% Triton6100, 0.1% NP40 and 16cocktail
inhibitor). After 30 min incubation on ice, the lysate was
centrifuged at 600 rcf/5 min/4uC). The supernatant was gently
decanted, and the nuclear pellet was resuspended in lysis buffer, 10
times the volume of the nuclei pellet, and sonicated on ice for
3 sec. The lysate was centrifuged at 600 rcf/5 min/4uC, and 1 mg
of supernatant was immunoprecipitated for CXCR4 (mouse
monoclonal, Santa Cruz) overnight at 4uC, followed by incubation
with Protein A/G Plus-Agarose beads (Santa Cruz) for 2 hrs at
4uC. CXCR4-bound agarose beads were separated from lysate by
a series of 3 washes with NP40 lysis buffer and centrifugation
(5000 pm/2 min/RT). The final wash was with 16 PBS. Beads
were processed for western blot analysis and membranes were
probed for Gai (Cell Signaling; 1:1000). Subsequently, the blots
were reprobed for CXCR4 with rabbit anti-CXCR4 (Santa Cruz,
1:500) antibody followed by incubation with mouse anti-rabbit
IgG (Cell Signaling) secondary antibody. Topoisomerase1 (Santa
Cruz) and anti-CD44 (Cell Signaling) were used to assess the
purity of nuclei lysates.
Intranuclear Calcium (Ca2+) Mobilization
Serum-starved PC3 cells (2.56105) were harvested to obtain
intact nuclei in NP-40 lysis buffer as described above, prior to
performing assay per the manufacturer’s instructions (Enzo Life
Sciences). Briefly, untreated isolated nuclei were resuspended in
100 ml of FluoForte dye-loading solution (Enzo Life Sciences) for
45 min at 37˚C and 15 min at RT, then centrifuged at 600 rcf/
5 min/RT. Solutions of AMD3100 (100 ng/ ml) and pertussis
toxin (PTX) (200 ng/ml) were prepared in calcium free, phenol
free RPMI. Nuclei samples were resuspended in 100 ml of
AMD3100 and PTX, aliquoted into black-walled, clear bottom
96well plates, and incubated for 1 hr. Next, the SDF1a was added
to samples in plates, (final dilution 100 ng/ ml) and incubated for
30 min at RT. Intranuclear calcium mobilization was determined
by the intensity (increase) of fluorescent (FluoForte)-bound Ca2+ in
the media. Results were measured on a microplate reader at
excitation 490 nm and emission 525 nm. Each sample was
prepared in triplicate per experiment, and performed at least
three times.
Statistical Analysis
Where applicable, data were analyzed by a paired student’s t-
test or ANOVA using GraphPad Prism (GraphPad) software. P
values less than 0.05 were considered significant.
Table 2. Multiple Sequence Alignment of the Nuclear Localization Sequence (NLS) Region in CXCR4.
Species Multiple sequence alignment
Human (NP003458.1) 130ISLDRYLAIVHATNSQRPRKLLAEKVVYVGVWIPALLLTIPDFIFANV177
Mouse (NP034041.2) 132ISLDRYLAIVHATNSQRPRKLLAEKAVYVGVWIPALLLTIPDFIFADVSQ181
Norway rat (NP071541.2) 127ISLDRYLAIVHATNSQRPRKLLAEKAVYVGVWIPALLLTIPDIIFADV174
Dog (NP001041491.1) 131ISLDRYLAIVHATNSQRPRKLLAEKVVYVGVWIPALLLTIPDFIFANV178
Chicken (NP989948.2) 140ISLDRYLAIVHATNSQRPRKLLAEKIVYVGVWLPAVLLTVPDIIFAST187
Chimpanzee (NP001009047.1) 130ISLDRYLAIVHATNSQRPRKLLAEKVVYVGVWIPALLLTIPDFIFANV177
HomoloGene database (NCBI) is a system for automated detection of homologs among the annotated genes of several completely sequenced eukaryotic genomes.
Sequences of input organisms are compared then matched into groups using a taxonomic tree built from sequence similarity; highly related organisms are matched up
first. http://www.ncbi.nlm.nih.gov/homologene/20739.
doi:10.1371/journal.pone.0057194.t002
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Results
CXCR4 is Expressed in the Nucleus of Prostate Tissues
Previous domain analysis of CXCR4 suggested that CXCR4
contains a nuclear targeting signal between amino acids 90–170
[73]. A bioinformatics analysis using the PSORT II NLS
prediction software (http://psort.ims.u-tokyo.ac.jp/) revealed a
putative nuclear localization sequence, ‘RPRK’ [72,74,75,76]
between amino acids 146–149 within CXCR4 (Table 1). Addi-
tionally, a HomoloGene/NCBI database search for the NLS
within CXCR4 revealed that ‘RPRK’ is been conserved among
species, including chicken, mouse, chimpanzee and others
(Table 2). Moreover, CXCR4 has been detected in the nucleus
of several cancer tissues [68,70]. Based on these data, we tested
whether CXCR4 protein could be detected within the nucleus of
prostate tissues. Using a prostate tissue microarray ranging from
normal to high-grade metastatic lesions, we detected positive
immunoreactivity for CXCR4 in prostate samples. Positive
immunoreactivity was detected as sporadic (CXCR4 positive cells
,5%), focal (CXCR4 positive cells .11%, but less than 50%), or
diffuse (CXCR4 positive cells .50%), compared to the average
total density of positive cells for CXCR4 (DAB stained). Samples
with immunohistochemical scores of negative, weak or moderate
staining, with sporadic to focal distributions, were considered to
have ‘low’ expression, whereas diffuse distributions of staining
were considered to have ‘high’ expression for CXCR4. Staining
intensity was sporadic to focal in the nucleus of low grade prostate
tissues (Fig. 1A), while high grade malignant tissues (Fig. 1A),
displayed an increased staining intensity and diffuse expression of
CXCR4 throughout the tissue compared to low grade. In both low
and high grade tumors, a fraction of CXCR4 clearly co-localized
with the nucleus. Staining intensity for CXCR4 was weak, or even
null, in normal tissues (Fig. 1A).
We have reported that PC3 cells were positive and 293T cells
were null, respectively, for CXCR4 protein [21]. To ensure the
specificity of CXCR4 monoclonal antibody (MAB172IgG2b) used
to detect its corresponding protein in the nucleus of prostate
tissues, we re-analyzed PC3 and 293T for CXCR4 with CXCR4
antibody (MAB172IgG2b) by western blot analysis (Fig. 1B).
Similar to our previous studies, CXCR4 was detected in PC3 but
not in 293T whole cell lysates (Fig. 1B). Subsequent analysis of cell
lysates by immunoprecipitation with MAB172 IgG2b followed by
western blot analysis with MAB172 IgG2b detected CXCR4 only
in PC3 lysates (Fig. 1C). To further confirm the specificity of
MAB172IgG2b to CXCR4, PC3 cell lysates were subjected to
immunoprecipitation with Fibronectin IgG2b, an isotype control,
followed by western blot analysis with MAB172 IgG2b (Fig. 1D).
Fibronectin was not detected by IP with CXCR4, but was detected
by western blot with a Fibronectin antibody (Fig. 1D).
CXCR4 is Present in Nuclear Fractions of Prostate Cancer
Cells
We used biochemical fractionation to confirm the nuclear
localization of CXCR4 detected in our tissue staining. PCa cell
lines were fractionated into nuclear and non-nuclear samples for
detection of CXCR4 by western blot analysis (Fig. 2A). We found
that normal prostate epithelial cells (RWPE1) were null for
CXCR4 [77]; however, three CXCR4-expressing PCa cell lines
(22RV1, DU145 and PC3) dually expressed CXCR4 in both
nuclear and non-nuclear fractions independent of SDF1a stimu-
lation (Fig. 2A). The purity of subcellular fractions was confirmed
by expression of CD44, a non-nuclear marker [78], and
topoisomerase 1, a nuclear marker [79], which ruled out the
possibility that expression of CXCR4 observed in nuclear fractions
was due to contamination.
We further confirmed CXCR4 in nuclei of PCa cell lines by
indirect immunohistochemistry (ICC) (Fig. 2B). In all three cell
lines, we found CXCR4 to be ubiquitously expressed throughout
the cells, or as distinct foci around the nucleus, at the PM and in
the cytoplasm, independent of SDF1a treatment. Collectively,
these observations suggest that CXCR4 is expressed at the PM,
but also associated with the nucleus of PCa cells.
A Putative NLS in CXCR4
Nuclear-localized PM receptors must contain a nuclear
localization sequence (NLS) to permit transport to and/or into
the nucleus [80]. To determine whether the PSORT II-predicted
NLS, ‘146RPRK149’ was functional and contributed to nuclear
expression of CXCR4, we evaluated the intracellular distribution
of wildtype GFP-tagged CXCR4 (pEGFPN1-CXCR4, GFP-
CXCR4 fusion protein), two mutated fusion proteins in which
arginine 146 and 148 were separately mutated to an alanine
(CXCR4R146A and CXCR4R148A, respectively), as well as a
fusion protein where the NLS was deleted (CXCR4DNLS).
Plasmids encoding GFP-CXCR4 were transfected into PC3 cells
and examined by ICC microscopy (Fig. 3). The localization
pattern of GFP-CXCR4 at the plasma membrane and in the
cytoplasm was consistent with endogeneous CXCR4 (Fig. 3A).
Previous studies have reported an expression pattern for GFP-
CXCR4 similar to our observation in other cancer cell lines
[81,82]. Wild-type GFP-tagged CXCR4 was localized predomi-
nantly at the PM, with some localization at the nucleus in
untreated cells (Fig. 3B). However, an increase in punctate staining
was observed at the nucleus/nuclear membrane upon treatment
with SDF1a. Interestingly, both CXCR4R146A (Fig. 3B) and
CXCR4R148A (data not shown) were detectable at the nucleus,
suggesting that neither R146A nor R148A mutations in the NLS
were sufficient to inhibit CXCR4 localization to the nucleus. To
further examine the requirement of this NLS to localize CXCR4
to the nucleus, we deleted the NLS, ‘146RPRK149’, within
pEGFPN1-CXCR4 (CXCR4DNLS). We detected CXCR4DNLS
at the PM and diffusely throughout the cytosol, similar to wild-type
Figure 2. Nuclear CXCR4 Expression in Prostate Cancer Cell Lines. A, Normal prostate epithelial (RWPE1) and PCa (PC3, DU145, 22RV1) cells
were stimulated with SDF1a (100 ng/ ml) prior to subcellular fractionation into non-nuclear and nuclear fractions. Immunoblots were probed with
anti-CXCR4. Anti-CD44 (non-nuclear) and anti-Topoisomerase1 (Topo 1, nuclear) were used as markers for fractionation purity and as loading
controls. The bar graphs are quantitative results of the band density representing expression of CXCR4 in each fraction. Data were mean +S.E. from
three independent experiments. *, P,0.05. B, Immunocytochemistry of PCa cell lines for CXCR4. PCa cells were stimulated with SDF1a (100 ng/ ml),
fixed with methanol, blocked then incubated with an antibody mixture containing a mouse anti-CXCR4 monoclonal antibody and a rabbit polyclonal
anti-Lamin A/C antibody, followed by secondary mixture containing a Cy3-conjugated anti-mouse antibody and FITC-conjugated anti-rabbit
antibody. Imaging was with a Zeiss LSM-510 UV Confocal Microscope using the 636 Plan-Apochromat 63x/1.40 Oil DIC objective at excitation
488 nm for FITC and 543 nm for Cy3. Confocal images demonstrating the plasma membrane and cytosolic localization of CXCR4 (red), intact nuclear
membrane (green), and nuclear-associated localization of CXCR4 (yellow/orange) are shown. Small arrows indicate co-localization of CXCR4 with the
nucleus (yellow/orange). Scale bars represent 50 mm.
doi:10.1371/journal.pone.0057194.g002
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GFP-CXCR4, but we did not detect CXCR4DNLS at the nucleus
(Fig. 3B). To further confirm that CXCR4DNLS was excluded
from the nucleus, PC3 cells were transiently transfected with
wildtype GFP-CXCR4 or CXCR4DNLS then fractionated into
nuclear and non-nuclear samples for analysis by western blot
analysis (Fig. 3C). Consistent with ICC observations, we found
that wild type GFP-CXCR4 and CXCR4DNLS were both
detectable in non-nuclear fractions, while only GFP-CXCR4
was detected in nuclear fractions. Collectively, these data suggest
that the ‘RPRK’ motif may be involved in localization of CXCR4
to the nucleus in prostate cancer.
CXCR4 Demonstrated an Interaction with Transportinb1
We identified a putative NLS motif that could be critical for
CXCR4 nuclear localization; however, the motif ‘RPRK’ is not a
typical classical NLS [60]. In fact, such sequences can also mediate
direct binding to other transport receptors. Among the different
molecules that are involved in the transport of various cargos to
the nucleus, members of the karyopherin beta (b) family contribute
directly or indirectly to the nuclear shuttling of molecules [83].
Transportinb1 (TRN1), also known as Karyopherinb2, is a
transport molecule of the importin-b family that has been linked
to desensitization [63] and nuclear-cytoplasmic shuttling of
receptors [84,85,86,87,88,89]. To test whether TRN1 was
involved in CXCR4 transport to the nucleus, we first established
that PC3 cells expressed TRN1 by western blot analysis (Fig. 4A);
293T cells served as a positive control for TRN1 expression. Next,
we tested for an interaction between CXCR4 and TRN1. We
immunoprecipitated CXCR4 from whole cell lysates and tested
for co-purification of TRN1 by western blot analysis. Figure 4B
demonstrates that CXCR4 and TRN1 associated in PC3 cell
lysates. To test whether the association between CXCR4 and
TRN1 led to CXCR4 translocation to the nucleus, we decreased
TRN1 protein expression by siRNA (Fig. 4C), then determined
CXCR4 localization by ICC. We first confirmed an effective
siRNA-mediated depletion of TRN1 by western blot analysis
(Fig. 4C). As previously described in control cells, CXCR4
localized to the PM, in the cytoplasm and in distinct foci around
the nucleus. When TRN1 expression was diminished, CXCR4
was undetectable around the nucleus, even in the presence of
SDF1a (Fig. 4D).
Nuclear-associated CXCR4 is Functional
Finally, we sought to determine whether CXCR4 receptors at
the nucleus are functional. Upon ligand stimulation and activa-
tion, GPCRs, including CXCR4, dissociates from a trimer of G-
proteins (Ga and Gbc) which initiates secondary signaling
pathways, such as increased cyclic AMP, increased intracellular
calcium levels, and others [90]. Thus, a reduction in the G-alpha
protein, Gai, associated with CXCR4 represents an active state of
a receptor. Therefore, we co-immunoprecipitated CXCR4 and
Gai and determined Gai expression levels by Western blot analysis,
to assess whether nuclear-associated CXCR4 was active. Whole
cells were stimulated with SDF1a then harvested to isolate intact
nuclei (Fig. 5A). Nuclei were lysed, then immunoprecipitated with
anti-CXCR4, prior to immunobloting for associated Gai. In
untreated cells, we observed a basal level in Gai expression, which
decreased upon treatment with SDF1a, suggesting that nuclear-
associated CXCR4 is functional and can respond to SDF1a.
We further tested the functionality of nuclear-associated
CXCR4 by assessing whether the receptor stimulated release of
intra-nuclear Ca2+. Isolated intact PC3 nuclei were incubated with
Ca2+-binding fluorescent probe (FluoForteH dye), then incubated
with CXCR4 antagonist, AMD3100, or Gai/Gao inhibitor
pertussis toxin (PTX), separately for one hour, followed by
treating with SDF1a. Calcium mobilization was determined by an
increase in fluorescent probe in the media, and measured at
ex = 490 nm/em = 525 nm. We observed a significant increase in
intra-nuclear Ca2+ release from nuclei stimulated with SDF1a,
compared to untreated samples. Further, AMD3100 antagonized
CXCR4 function, which resulted in decreased Ca2+ levels, lower
than SDF1a-treated samples. PTX prevents G-proteins from
interacting with GPCRs, thus interfering with intracellular
communication. As such, we did not observe an increase in
Ca2+-mobilization in PTX-treated nuclei, even in the presence of
SDF1a, supporting that the intra-nuclear Ca2+ surge was evoked
by CXCR4, yet sensitive to PTX inhibition. Our results are in
agreement with earlier studies that observed functional GPCRs
associated with the nucleus, and that these nuclear GPCRs
mobilized Ca2+ [40,91,92].
Discussion
This study established that CXCR4 receptor protein is
expressed in PCa cells and is associated with the nucleus in these
cells. Additionally, we provide insight into a specific nuclear
protein import mechanism that contributes to nuclear localization
of CXCR4. Importantly, CXCR4 responded to its ligand, SDF1a,
at the nucleus. Nuclear localization of CXCR4 may be a
mechanism by which prostate cancer cells employ to survive,
even after the insult of chemotherapy. Therefore, antagonizing
nuclear transport pathways and/or the action of nuclear CXCR4,
could provide a rational approach to prevention and management
of prostate cancer.
PCa mortality is often a result of metastasis to secondary organs.
CXCR4 is involved in the metastatic spread of primary tumor cells
through activation of requisite pathways, which signals to
downstream targets for invasion and movement through the
vasculature, the establishment of a blood supply at the new tumor
site and inhibition of immunosurveillance mechanisms that will
destroy the new tumor [22]. Taichman et al. [23] initially observed
that CXCR4 facilitated PCa metastasis to the bone, the primary
site of distal PCa colonization. SDF1a was constitutively expressed
in the bone marrow by osetoblasts, fibroblasts, and endothelial
Figure 3. A Putative Functional NLS within CXCR4. A, GFP-CXCR4 fusion protein localized similar to endogenous CXCR4. CXCR4-pEGFPN1
transfected PC3 cells were stimulated with SDF1a, fixed with methanol, blocked then incubated with a mouse anti-CXCR4 monoclonal antibody,
followed by a Cy3-conjugated anti-mouse secondary antibody. Nuclei were stained with DAPI (blue). Images were taken at 406maginification using
Axiovision software 4.8.2 with a Zeiss Axio Imager.z1 fluorescence microscope at ex = 470 nm for FITC, ex = 358 nm for DAPI and ex = 551 nm for Cy3.
Images demonstrate the co-localization (yellow) of endogenous CXCR4 (red) with GFP-tagged CXCR4 (green). B, Localization analysis of wild type
CXCR4 (CXCR4-pEGFPN1), NLS-mutant of CXCR4 (pEGFPN1-CXCR4R146A,) and deleted NLS of CXCR4 (CXCR4DNLS) by immunocytochemistry in PC3
cells. Nuclei were stained with propidium iodide (red) and CXCR4 was detected as the fusion protein GFP-CXCR4 (green). Imaging was with a Zeiss
LSM-510 UV Confocal Microscope using the 636Plan-Apochromat 63x/1.40 Oil DIC objective at ex = 488 nm for FITC and ex = 543 nm for Cy3. Scale
bars represent 50 mm. C, Transfected cells were stimulated with SDF1a prior to subcellular fractionation into non-nuclear and nuclear fractions.
Immunoblots were probed with anti-GFP to detect the fusion protein GFP-CXCR4. Anti-CD44 (non-nuclear) and anti-Topoisomerase1 (Topo 1,
nuclear) were used as markers for fractionation purity and as loading controls.
doi:10.1371/journal.pone.0057194.g003
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Figure 4. CXCR4 and TRN1 Demonstrate an Interaction. A, Sixty micrograms of total protein were analyzed for TRN1 expression by western
blot analysis using a TRN1 specific antibody. Alpha-tubulin served as a loading control. B, One milligram of PC3 whole cell lysate was
immunoprecipitated with anti-CXCR4 and separated by SDS-PAGE. Immunocomplexes were probed with anti-TRN1 or anti-CXCR4 to ensure that
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cells, which directed cell migration, by attracting PCa cells that
expressed CXCR4 on the plasma membrane. To date, CXCR4,
like all GPCRs, is regarded as a plasma membrane receptor.
However, an emerging concept is that GPCRs are translocated to
the nucleus and other intracellular organelles, possibly after
internalization [93]. For instance, Wright et al. reported that
endogenous a1-adrenergic receptors (a1-ARs) localized to and
signaled at nuclei in adult cardiac myocytes [94], and in 2012, the
group described that a1-AR nuclear localization drove the
formation of receptor oligomers and regulated signaling in adult
cardiac myocytes [95], suggesting that GPCRs at the nucleus
exhibited the same behavior as their PM counterparts.
The biochemical mechanisms of CXCR4 intracellular localiza-
tion to the nucleus, and subsequent functions, are not well
understood. The generally accepted view of CXCR4 localization
and signaling centers upon a PM-localized receptor that is
activated by an extracellular ligand, SDF1a. This ligand then
initiates intracellular signals through G-proteins that support
favorable responses for tumor development. Following activation
and subsequent signaling, the canon concept of events is that
CXCR4 is rapidly internalized from the PM to attenuate signaling
communication, and then recycled back to the PM as an
inactivated receptor, or sorted to the lysosome for degradation;
both processes are important for receptor signal termination
CXCR4 interacted with TRN1 and was immunoprecipitated, respectively. Thirty micrograms of whole cell PC3 supernatant, post-immunoprecipitation,
were separated by SDS-PAGE and harvested for western blot analysis to assess the efficiency of CXCR4 immunoprecipitation. C and D, Cells were
transiently transfected with TRN1-specific siRNA to determine an effective concentration (C), prior to harvesting for immunohistochemistry with anti-
Lamin A/C and anti-CXCR4 (D). Images were taken using Zeiss Axio Imager.z1 fluorescence microscope at 406magnification at excitation 470 nm for
FITC and 551 nm for Cy3. Small arrows indicate co-localization of CXCR4 with the nucleus (yellow/orange). Scale bar represents 50 mm.
doi:10.1371/journal.pone.0057194.g004
Figure 5. Nuclear CXCR4 was Functional at the Nucleus. A, Representative light images of whole cells and isolated nuclei confirmed the
integrity of nuclear isolation at 206magnification. B, Whole cells were treated with SDF1a prior to isolating and lysing intact nuclei. Nuclei lysates
(1 mg) were immunoprecipitated with anti-CXCR4 and separated by SDS-PAGE. Immunocomplexes were probed for Gai (first row) or CXCR4 antibody
(second row), respectively. Anti-CD44 (non-nuclear) and anti-Topoisomerase1 (Topo1, nuclear) were used as markers for fractionation purity and as
loading controls. C, PC3 nuclei were isolated, incubated with FluoForte dye Ca2+ probe, followed by incubation with AMD3100 or pertussis toxin (PTX)
for 1 hr, then stimulated with SDF1a for 30 min. An increase in fluorescent-bound Ca2+ was measured on a microplate reader at ex = 490 nm/
em=525 nm.
doi:10.1371/journal.pone.0057194.g005
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[96,97,98]. Consistent with our findings reported here, GPCRs
that have been detected at the nucleus were reported to have
originated from the PM [38,40,99,100].
The results of this study support an alternately-localized and
functional CXCR4 receptor. As assessed by decreased Gai
expression and Ca2+ mobilization in the presence of SDF1a,
CXCR4 participates in intra-nuclear signaling at the nucleus.
Nuclear CXCR4 was initially observed in diverse tumor tissues
[69,70,101,102,103] and correlated with significant predictors for
poor overall malignant survival [103], lymphovascular invasion
[104] and lymph node metastasis [105]. Our findings extended
these observations further and provide evidence that: (i) CXCR4
was present at the nucleus of prostate tumor tissues and cell lines;
(ii) nuclear CXCR4 contained a putative, functional NLS which
excluded CXCR4 from the nucleus when deleted; and (iii)
CXCR4 associated with TRN1 and depletion of TRN1 decreased
localization of CXCR4 to the nucleus.
To date, considerable evidence supports the presence of GPCRs
at the PM, or within the perinuclear/nuclear compartments of
cells, following ligand activation [40,99,106,107]. It is well known
that CXCR4 is highly expressed in malignant PCa cells [108] and
is involved in metastasis [21,22,24,109]; however, few reports have
observed a subcellular localization for CXCR4 other than the PM
and endosomes in tumor tissues. We observed positive staining for
CXCR4 in the nucleus of PCa tissues; furthermore, the amount of
nuclei positively stained for CXCR4 increased with the grade of
the tumor. In PCa cell lines, unexpectedly, we detected CXCR4 in
nuclear fractions of untreated cells; nuclear CXCR4 expression
increased with SDF1a stimulation. Sun et al. demonstrated that
PCa cells expressed SDF1a mRNA and secreted a biologically
active protein [110]. Perhaps the nuclear expression of CXCR4 in
untreated cells may result from autocrine signaling [111,112].
Endogenous SDF1a ligand secreted by PCa cells may act upon
PM-localized CXCR4 in an autocrine manner, resulting in
receptor internalization and subsequent nuclear targeting of
CXCR4. Our results do not support a correlation between
increased nuclear CXCR4 expression and PCa metastasis, or the
clinical relevance of nuclear CXCR4 expression in predicting PCa
prognosis survival. However, Woo et al. predicted that high
expression of nuclear CXCR4 in hormone receptor negative
breast cancer was associated with the high possibility of lymph
node metastasis [113].
The origin and functional relevance of nuclear CXCR4, and
the precise mechanisms involved in its nuclear translocation, have
yet to be established. Wang et al. presumed the presence of a non-
traditional, nuclear localization sequence, ‘146RPRK149’, within
CXCR4, using C-terminal deletant plasmid constructs to reveal
expression of CXCR4 at the nucleus [73]. Nuclear localization
sequences are a stretch of positively charged, highly basic amino
acids (lysines or arginines) [114] and are divided into two types: (i)
the classical monopartite type containing a single cluster of 4–6
lysine(K)/arginine (R) amino acid residues; and the (ii) the
bipartite type contains two clusters of basic amino acid residues
separated by 10–12 amino acids [115]. The majority of non-
classical types of NLSs consist of a single 20–40 long stretch of
non-basic amino acids [116,117,118]. Some non-classical NLSs do
not follow these rules, as they consist of a single short stretch of one
or more basic amino acids that are distinct from the monopartite
NLS [66,119,120,121,122], such as the motif ‘RPRK’. Ren et al.
reported that mammalian target of rapamycin (mTOR) contained
‘RPRK’, and upon deletion, onion cells loss nuclear expression of
mTOR [75].
Transportinb1 studies on plasma membrane GPCRs have
reported that they are functional and able to initiate signaling at
the nucleus [38,40,91,99]. Of particular interest, the importins
beta, to which TRN1 belongs, were involved in nuclear
localization of GPCRs, such as angiotensin 1, opiod growth
factor, fibroblast growth factor receptors and CCR2 chemokine
receptor [57,84,88,123,124,125]. The canon concept of GPCR
signaling is that signal transduction cascades are initiated at the
PM, but not at the nuclear membrane. However, this concept has
been disapproved by evidence which demonstrated that the
nuclear envelope plays a major role in signaling cascades. For
instance, GPCR-associated heterotrimeric G proteins [126], and
downstream signaling molecules, such as adenylate cyclase [127],
phospholipase C [128] and phospholipase D [126], have been
found localized at the nucleus. Moreover, nuclear membranes
have been shown to possess signaling molecules such as 1,4,5-
triphosphate and inositol 1,3,4,5-tetrakisphosphate [128], further
confirming the role that nuclear membranes play in signal
transduction. We observed that nuclear CXCR4 was associated
with Gai in untreated samples; Gai dissociated from CXCR4 upon
SDF1a stimulation, compared to untreated samples, further
confirming that nuclear CXCR4 is functional. Most studies that
have reported functional nuclear GPCRs observed an increase in
intra-nuclear Ca2+ levels upon stimulation with an appropriate
agonist [40,45,91], emphasizing an importance of nuclear GPCRs
to cells, since nuclear Ca2+ play pivotal roles in nuclear functions
(cell division, proliferation, protein import, apoptosis, and gene
transcription) [129]. Among the various reports where nuclear
calcium was mobilized from organelles, such as the cytoplasm
[130], nuclear lumen [131] and nucleoplasmic reticulum [132],
the latter two have been suggested to increase/enhance signals
initiated in the cytoplasm, and/or generate its own Ca2+ transients
[131,133]. Additionally, the amplitude and duration of calcium
signals have also been shown to differentially control activation of
transcription factors [134]. For instance, transcription factors, such
as NF-kB, c-Jun, and N-terminal kinase are activated by transient
increases in Ca2+[134]. Taken together, data herein, and by our
colleagues, emphasize a secondary GPCR signaling network at the
nucleus, which may ensure, or enhance, the communication and
coordination of numerous biochemical signals that are critical in
regulating tumorigenic paradigms within the cell.
In conclusion, the data presented provides the first clear
evidence of CXCR4 located at the nucleus of cancer cells and
existing as a functional, ligand-responsive receptor in advanced
metastatic PCa cells. Therefore, antagonizing the action of nuclear
CXCR4 could provide a rational approach to the prevention and
management of PCa metastasis. Lee et al. [135] described a unique
survival system in breast cancer cells by which VEGF acted as an
intracrine survival factor through its binding to nuclear VEGFR1.
This theory may hold true for tumor cells that express CXCR4 at
the nucleus, and secrete SDF1a from the same cell. This study is
significant to therapeutic development, as a functional CXCR4
receptor that can initiate signaling from inside the cell may escape
from chemotherapeutic agents that are designed to antagonize the
PM receptor, and/or cannot pass through the hydrophobic
regions of the PM to reach nuclear receptors.
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